House Oversight filing lists multiple LLCs and assets with vague valuationsTime: 09/18/18 07:48:46 AM (558974926)
1 duplicate copy in the archive
Title Match
Case Filed-35025House OversightSanofi and Regeneron press release on Praluent clinical trial results and pricing
November 11, 20251p2 persons
Case File
d-35025House OversightSanofi and Regeneron press release on Praluent clinical trial results and pricing
Other
The passage is a standard pharmaceutical press release describing trial efficacy, safety, pricing, and upcoming regulatory steps. It contains no allegations, financial flows, or connections to high‑pr Phase III trial data showing LDL cholesterol reduction with Praluent. Wholesale Acquisition Cost disclosed at $40 per day. Announcement of EMA CHMP positive opinion and pending EU approval.
Date
November 11, 2025
Source
House Oversight
Reference
House Oversight #025891
Pages
1
Persons
2
Integrity
No Hash Available
Loading document viewer...
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.
Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.